Solara Active Pharma Sciences Q2 FY26 results (Jul–Sep 2025) and concall

Solara Active Pharma Sciences reported a challenging Q2 FY26 with a marginal revenue decline to INR314 crores and a significant 39% Q-o-Q EBITDA degrowth to INR35 crores, primarily due to an unscheduled operational shutdown at its Mangalore facility. Despite these short-term disruptions, the company maintained a healthy gross margin of 51% and successfully cleared a US FDA audit. Management acknowledged liquidity concerns with net current liabilities exceeding assets but outlined a clear debt reduction plan and a focus on profitable growth.